Chronos Archive seal
The Human Record

Lorraine Hansberry

Case HR-ML034 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
May 19, 1930 – January 12, 1965
Synthetic DOB
1993-05-19
Index visit
2026-04-20 at age 32
Synthetic MRN
HR-ML034-SYN

Teaching objective: Recognize pancreatic cancer in a young Black woman whose epigastric and back pain, weight loss, new diabetes and iron deficiency anemia could be put down to an ulcer or to stress, and care for it on the NCCN pancreatic adenocarcinoma guideline and the ASCO guidelines on potentially curable pancreatic cancer, palliative care and supportive care: pancreas-protocol CT and endoscopy at once; tissue by endoscopic ultrasound and biliary drainage before CA 19-9 is read; resectability staging and a multidisciplinary tumor board; germline genetic testing for every patient with pancreatic cancer and molecular profiling of the tumor; modified FOLFIRINOX before surgery for borderline resectable disease, with dose and support matched to her fitness; pancreaticoduodenectomy and chemotherapy after it; palliative care from the day of diagnosis; pain, nutrition and pancreatic enzyme replacement; diabetes caused by the pancreatic disease; venous thromboembolism risk; fertility and contraception; plain disclosure of the diagnosis and its prognosis; and a plan built around her wish to keep writing. Black Americans with pancreatic cancer are less often offered surgery and have worse survival, so each step is checked for delay.

Historical timeline

DateEventClaims
May 19, 1930Born in Chicago.CLM-0001
1940The Supreme Court decides Hansberry v. Lee, the family's challenge to a restrictive covenant.CLM-0002
1946Her father dies suddenly in Mexico.CLM-0003
June 1953Marries Robert Nemiroff, three years after leaving Wisconsin for New York.CLM-0004
March 11, 1959A Raisin in the Sun opens on Broadway, the first play by a Black woman produced there.CLM-0005
April 1963Fainting spells and attacks of nausea begin, first thought to be a duodenal ulcer.CLM-0006
By June 1963After a collapse in pain and a ten-day admission in which cancer is diagnosed (she is told of anemia and bleeding ulcers), an unsuccessful operation in New York.CLM-0007, CLM-0008, CLM-0011
August 1963Surgery at the Lahey Clinic at the New England Baptist Hospital in Boston.CLM-0008
1964Gives the To Be Young, Gifted and Black speech on an afternoon out of hospital; The Sign in Sidney Brustein's Window opens in October.CLM-0009
January 12, 1965Dies of cancer at University Hospital in New York at 34.CLM-0010, CLM-0011

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Lorraine Vivian Hansberry was born in Chicago on May 19, 1930, the youngest of four children of Carl Augustus Hansberry, a successful real estate broker who founded one of the city's first Black banks, and Nannie Louise (Perry) Hansberry, a schoolteacher. Her grandfather had been born enslaved. confirmed Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports
Harris J. Hansberry, Lorraine Vivian (Scribner Encyclopedia of American Lives, Thematic Series: The 1960s) supports
Lorraine Hansberry supports
HISTMED Master Roster v3 context
D In 1937 her family moved into a house in the all-white Washington Park subdivision of Woodlawn in defiance of a racially restrictive covenant. The resulting case, Hansberry v. Lee, was decided in the family's favor by the U.S. Supreme Court in 1940.
Anchors the modern social history: a writer whose family fought housing segregation in court when she was a child.
confirmed Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports
Harris J. Hansberry, Lorraine Vivian (Scribner Encyclopedia of American Lives, Thematic Series: The 1960s) supports
D Her father died suddenly in Mexico in 1946 of a cerebral hemorrhage while planning to move the family there.
Family history entry; no other family medical history was found in the cited sources.
confirmed Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports
D She enrolled at the University of Wisconsin in 1948, left in 1950 for New York, and wrote for the newspaper Freedom. In June 1953 she married Robert Nemiroff. Sources differ on when they divorced (1962 or 1964); they continued to work together.
Her working life as a writer anchors the modern social history; the marriage is recorded only as the sources state it.
confirmed Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports
Harris J. Hansberry, Lorraine Vivian (Scribner Encyclopedia of American Lives, Thematic Series: The 1960s) supports
Lorraine Hansberry supports
Powers N. Hansberry, Lorraine (1930-1965) (Women in World History: A Biographical Encyclopedia) supports
D A Raisin in the Sun opened at the Ethel Barrymore Theatre on Broadway on March 11, 1959, the first play by a Black woman to be produced on Broadway. It won the New York Drama Critics' Circle Award; she was the first Black playwright and, at 29, the youngest American to win it. In 1962 she moved to Croton-on-Hudson, New York.
Her documented career anchors the modern social history: a playwright at work on her next play.
confirmed Lorraine Hansberry supports
Harris J. Hansberry, Lorraine Vivian (Scribner Encyclopedia of American Lives, Thematic Series: The 1960s) supports
Lorraine Hansberry supports
Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports
D One account dates the start of her illness to April 1963, when she began to suffer from fainting spells and attacks of nausea; tests pointed at first to what was suspected to be a duodenal ulcer.
The anchor for the modern presenting problem (epigastric pain, nausea and near-fainting with iron deficiency anemia). The month comes from one reference work only.
probable Powers N. Hansberry, Lorraine (1930-1965) (Women in World History: A Biographical Encyclopedia) supports
D In 1963 she had an attack, collapsed in pain and was in hospital for ten days, during which doctors diagnosed cancer; she was told she had anemia and bleeding ulcers.
The documented diagnosis to which the modern diagnosis is linked. That she was not told the diagnosis is the historical contrast with the modern episode, in which it is explained to her plainly. The month is not given.
probable Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports
D She had an unsuccessful operation in New York in June 1963 and surgery at the Lahey Clinic at the New England Baptist Hospital in Boston in August 1963; one account dates the operations to June 24 and August 2, and neither cured the cancer.
Documented surgery after the index date; the modern episode's operation is synthetic.
confirmed Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports
Lorraine Hansberry supports
D She kept writing and speaking through her illness. In May 1964, released from the hospital for the afternoon, she gave the speech that became known as To Be Young, Gifted and Black; in June she left her sickbed for a Town Hall debate; and in the fall she moved to a hotel near the rehearsals of The Sign in Sidney Brustein's Window, attending its opening night in October 1964.
Her documented wish to keep working anchors the modern plan built around her writing.
confirmed Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports
Powers N. Hansberry, Lorraine (1930-1965) (Women in World History: A Biographical Encyclopedia) supports
D She died of cancer at University Hospital in New York on January 12, 1965, at 34; The Sign in Sidney Brustein's Window closed that night. Her funeral was held in Harlem on January 15.
The documented death from cancer, to which the synthetic diagnosis is linked. History only, stated without detail.
confirmed Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports
Powers N. Hansberry, Lorraine (1930-1965) (Women in World History: A Biographical Encyclopedia) supports
Lorraine Hansberry supports
Lorraine Hansberry supports
R The primary site of her cancer is recorded differently: most reference works give pancreatic cancer; the PBS American Masters timeline gives cancer of the duodenum; and Women in World History describes colon cancer that had spread to the pancreas. One biography dates the diagnosis to 1964 rather than 1963.
Retrospective; the sources disagree and no pathology was found. The modern episode uses a pancreatic head adenocarcinoma invading the duodenum, which is compatible with the accounts of pancreatic and duodenal cancer; this is a teaching choice, not a resolution of the historical question.
disputed Lorraine Hansberry supports
Lorraine Hansberry supports
Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) supports
Powers N. Hansberry, Lorraine (1930-1965) (Women in World History: A Biographical Encyclopedia) supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this week resolved confirmed active CLM-0006
S Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mL active confirmed active CLM-0006
S New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2 resolved confirmed active CLM-0006
S Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differently active confirmed both_with_link CLM-0007, CLM-0010, CLM-0011
S Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dL active confirmed active CLM-0007, CLM-0010
S Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight loss active confirmed active CLM-0007, CLM-0010
S Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by it active confirmed active CLM-0007, CLM-0010
S Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCP resolved confirmed active CLM-0007, CLM-0010
S Chemotherapy-induced diarrhea from irinotecan, grade 2 (five to six watery stools a day above her usual), starting on day 3 of cycle 5, with low potassium and magnesium and mild dehydration; no fever, blood or neutropenia; resolved resolved confirmed active CLM-0007, CLM-0010
S Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttons active confirmed active CLM-0007, CLM-0010
S After pylorus-preserving pancreaticoduodenectomy with superior mesenteric vein resection: loss of the head of the pancreas, with more marked exocrine insufficiency and insulin-requiring diabetes active confirmed active CLM-0007, CLM-0010

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-04-20 Hemoglobin [Mass/volume] in Blood 9.1 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-04-20 MCV [Entitic mean volume] in Red Blood Cells by Automated count 74 fL (low)
Reference 80-100 fL
http://loinc.org · 787-2
S 2026-04-20 Leukocytes [#/volume] in Blood by Automated count 7.4 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-04-20 Platelets [#/volume] in Blood by Automated count 388 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-04-20 Ferritin [Mass/volume] in Serum or Plasma 6 ng/mL (low)
Reference 15-150 ng/mL
http://loinc.org · 2276-4
S 2026-04-20 Sodium [Moles/volume] in Serum or Plasma 138 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-04-20 Potassium [Moles/volume] in Serum or Plasma 4 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-04-20 Creatinine [Mass/volume] in Serum or Plasma 0.7 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-04-20 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 118 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-04-20 Glucose [Mass/volume] in Serum or Plasma 132 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-04-20 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 48 U/L (high)
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-04-20 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 41 U/L (high)
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-04-20 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 236 U/L (high)
Reference 35-104 U/L
http://loinc.org · 6768-6
S 2026-04-20 Bilirubin.total [Mass/volume] in Serum or Plasma 1.6 mg/dL (high)
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-04-20 Albumin [Mass/volume] in Serum or Plasma 3.6 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-04-20 Lipase [Enzymatic activity/volume] in Serum or Plasma 52 U/L
Reference 13-60 U/L
http://loinc.org · 3040-3
S 2026-04-20 Hemoglobin A1c/Hemoglobin.total in Blood 6.6% (high)
Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes
http://loinc.org · 4548-4
S 2026-04-20 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 2026-04-20 Pain severity - 0-10 verbal numeric rating [Score] - Reported 5 http://loinc.org · 72514-3
S 2026-05-04 Hemoglobin [Mass/volume] in Blood 10.4 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-05-04 Leukocytes [#/volume] in Blood by Automated count 7 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-05-04 Neutrophils [#/volume] in Blood by Automated count 4.6 10*3/uL
Reference 1.5-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-05-04 Platelets [#/volume] in Blood by Automated count 366 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-05-04 Creatinine [Mass/volume] in Serum or Plasma 0.68 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-05-04 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 119 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-05-04 Glucose [Mass/volume] in Serum or Plasma 141 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-05-04 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 30 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-05-04 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-05-04 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 168 U/L (high)
Reference 35-104 U/L
http://loinc.org · 6768-6
S 2026-05-04 Bilirubin.total [Mass/volume] in Serum or Plasma 0.9 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-05-04 Albumin [Mass/volume] in Serum or Plasma 3.5 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-05-04 Cancer Ag 19-9 [Units/volume] in Serum or Plasma 486 U/mL (high)
Reference <=35 U/mL
http://loinc.org · 24108-3
S 2026-05-04 Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 3.9 ng/mL (high)
Reference Up to 3.0 ng/mL in non-smokers
http://loinc.org · 2039-6
S 2026-05-04 INR in Platelet poor plasma by Coagulation assay 1
Reference 0.8-1.2
http://loinc.org · 6301-6
S 2026-05-04 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 7 http://loinc.org · 44261-6
S 2026-05-04 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 8 http://loinc.org · 70274-6
S 2026-05-04 Pain severity - 0-10 verbal numeric rating [Score] - Reported 6 http://loinc.org · 72514-3
S 2026-06-29 Hemoglobin [Mass/volume] in Blood 11.2 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-06-29 Leukocytes [#/volume] in Blood by Automated count 8.9 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-06-29 Neutrophils [#/volume] in Blood by Automated count 5.8 10*3/uL
Reference 1.5-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-06-29 Platelets [#/volume] in Blood by Automated count 214 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-06-29 Creatinine [Mass/volume] in Serum or Plasma 0.72 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-06-29 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 114 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-06-29 Glucose [Mass/volume] in Serum or Plasma 128 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-06-29 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-06-29 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-06-29 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 120 U/L (high)
Reference 35-104 U/L
http://loinc.org · 6768-6
S 2026-06-29 Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-06-29 Albumin [Mass/volume] in Serum or Plasma 3.5 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-06-29 Magnesium [Mass/volume] in Serum or Plasma 1.9 mg/dL
Reference 1.7-2.2 mg/dL
http://loinc.org · 19123-9
S 2026-06-29 Ferritin [Mass/volume] in Serum or Plasma 88 ng/mL
Reference 15-150 ng/mL
http://loinc.org · 2276-4
S 2026-06-29 Cancer Ag 19-9 [Units/volume] in Serum or Plasma 210 U/mL (high)
Reference <=35 U/mL
http://loinc.org · 24108-3
S 2026-06-29 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 8 http://loinc.org · 44261-6
S 2026-06-29 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 9 http://loinc.org · 70274-6
S 2026-06-29 Pain severity - 0-10 verbal numeric rating [Score] - Reported 2 http://loinc.org · 72514-3
S 2026-07-16 Hemoglobin [Mass/volume] in Blood 11 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-07-16 Leukocytes [#/volume] in Blood by Automated count 6.2 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-07-16 Neutrophils [#/volume] in Blood by Automated count 4.1 10*3/uL
Reference 1.5-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-07-16 Platelets [#/volume] in Blood by Automated count 188 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-07-16 Sodium [Moles/volume] in Serum or Plasma 134 mmol/L (low)
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-07-16 Potassium [Moles/volume] in Serum or Plasma 3.2 mmol/L (low)
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-07-16 Creatinine [Mass/volume] in Serum or Plasma 0.94 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-07-16 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 83 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-07-16 Glucose [Mass/volume] in Serum or Plasma 118 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-07-16 Magnesium [Mass/volume] in Serum or Plasma 1.6 mg/dL (low)
Reference 1.7-2.2 mg/dL
http://loinc.org · 19123-9
S 2026-08-10 Hemoglobin [Mass/volume] in Blood 10.9 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-08-10 Leukocytes [#/volume] in Blood by Automated count 7.8 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-08-10 Neutrophils [#/volume] in Blood by Automated count 4.9 10*3/uL
Reference 1.5-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-08-10 Platelets [#/volume] in Blood by Automated count 176 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-08-10 Sodium [Moles/volume] in Serum or Plasma 138 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-08-10 Potassium [Moles/volume] in Serum or Plasma 4.1 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-08-10 Creatinine [Mass/volume] in Serum or Plasma 0.76 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-08-10 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 107 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-08-10 Glucose [Mass/volume] in Serum or Plasma 124 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-08-10 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-08-10 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-08-10 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 98 U/L
Reference 35-104 U/L
http://loinc.org · 6768-6
S 2026-08-10 Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-08-10 Albumin [Mass/volume] in Serum or Plasma 3.6 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-08-10 Hemoglobin A1c/Hemoglobin.total in Blood 7% (high)
Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes
http://loinc.org · 4548-4
S 2026-08-10 Cancer Ag 19-9 [Units/volume] in Serum or Plasma 41 U/mL (high)
Reference <=35 U/mL
http://loinc.org · 24108-3
S 2026-08-10 INR in Platelet poor plasma by Coagulation assay 1
Reference 0.8-1.2
http://loinc.org · 6301-6
S 2026-08-10 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 http://loinc.org · 44261-6
S 2026-08-10 Pain severity - 0-10 verbal numeric rating [Score] - Reported 1 http://loinc.org · 72514-3
S 2026-10-05 Hemoglobin [Mass/volume] in Blood 10.6 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-10-05 Leukocytes [#/volume] in Blood by Automated count 8.2 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-10-05 Neutrophils [#/volume] in Blood by Automated count 5.1 10*3/uL
Reference 1.5-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-10-05 Platelets [#/volume] in Blood by Automated count 302 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-10-05 Sodium [Moles/volume] in Serum or Plasma 137 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-10-05 Potassium [Moles/volume] in Serum or Plasma 4.3 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-10-05 Creatinine [Mass/volume] in Serum or Plasma 0.71 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 2026-10-05 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 116 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-10-05 Glucose [Mass/volume] in Serum or Plasma 156 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-10-05 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-10-05 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 2026-10-05 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 110 U/L (high)
Reference 35-104 U/L
http://loinc.org · 6768-6
S 2026-10-05 Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-10-05 Albumin [Mass/volume] in Serum or Plasma 3.4 g/dL (low)
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-10-05 Cancer Ag 19-9 [Units/volume] in Serum or Plasma 18 U/mL
Reference <=35 U/mL
http://loinc.org · 24108-3
S 2026-10-05 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 7 http://loinc.org · 44261-6
S 2026-10-05 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 6 http://loinc.org · 70274-6
S 2026-10-05 Pain severity - 0-10 verbal numeric rating [Score] - Reported 2 http://loinc.org · 72514-3
S 2026-10-21 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 http://loinc.org · 44261-6
S 2026-10-05 Albumin/Creatinine [Mass Ratio] in Urine 12 mg/g
Reference <=30 mg/g
http://loinc.org · 9318-7

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-04-20Body height163 cm8302-2S
2026-04-20Body weight56.2 kg29463-7S
2026-04-20Body mass index (BMI) [Ratio]21.2 kg/m239156-5S
2026-04-20Systolic blood pressure104 mm[Hg]8480-6S
2026-04-20Diastolic blood pressure66 mm[Hg]8462-4S
2026-04-20Heart rate102 /min8867-4S
2026-04-20Respiratory rate16 /min9279-1S
2026-04-20Body temperature36.8 Cel8310-5S
2026-04-20Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-05-04Body height163 cm8302-2S
2026-05-04Body weight55.4 kg29463-7S
2026-05-04Body mass index (BMI) [Ratio]20.9 kg/m239156-5S
2026-05-04Systolic blood pressure108 mm[Hg]8480-6S
2026-05-04Diastolic blood pressure68 mm[Hg]8462-4S
2026-05-04Heart rate92 /min8867-4S
2026-05-04Respiratory rate16 /min9279-1S
2026-05-04Body temperature36.7 Cel8310-5S
2026-05-04Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-06-29Body height163 cm8302-2S
2026-06-29Body weight54.8 kg29463-7S
2026-06-29Body mass index (BMI) [Ratio]20.6 kg/m239156-5S
2026-06-29Systolic blood pressure110 mm[Hg]8480-6S
2026-06-29Diastolic blood pressure70 mm[Hg]8462-4S
2026-06-29Heart rate84 /min8867-4S
2026-06-29Respiratory rate16 /min9279-1S
2026-06-29Body temperature36.6 Cel8310-5S
2026-06-29Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-08-10Body height163 cm8302-2S
2026-08-10Body weight54.2 kg29463-7S
2026-08-10Body mass index (BMI) [Ratio]20.4 kg/m239156-5S
2026-08-10Systolic blood pressure112 mm[Hg]8480-6S
2026-08-10Diastolic blood pressure72 mm[Hg]8462-4S
2026-08-10Heart rate80 /min8867-4S
2026-08-10Respiratory rate16 /min9279-1S
2026-08-10Body temperature36.6 Cel8310-5S
2026-08-10Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-10-05Body height163 cm8302-2S
2026-10-05Body weight51.8 kg29463-7S
2026-10-05Body mass index (BMI) [Ratio]19.5 kg/m239156-5S
2026-10-05Systolic blood pressure106 mm[Hg]8480-6S
2026-10-05Diastolic blood pressure68 mm[Hg]8462-4S
2026-10-05Heart rate86 /min8867-4S
2026-10-05Respiratory rate16 /min9279-1S
2026-10-05Body temperature36.7 Cel8310-5S
2026-10-05Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-07-16Body height163 cm8302-2S
2026-07-16Body weight53.6 kg29463-7S
2026-07-16Body mass index (BMI) [Ratio]20.2 kg/m239156-5S
2026-07-16Systolic blood pressure98 mm[Hg]8480-6S
2026-07-16Diastolic blood pressure62 mm[Hg]8462-4S
2026-07-16Heart rate104 /min8867-4S
2026-07-16Respiratory rate16 /min9279-1S
2026-07-16Body temperature37.1 Cel8310-5S
2026-07-16Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-10-21Body height163 cm8302-2S
2026-10-21Body weight52.4 kg29463-7S
2026-10-21Body mass index (BMI) [Ratio]19.7 kg/m239156-5S
2026-10-21Systolic blood pressure106 mm[Hg]8480-6S
2026-10-21Diastolic blood pressure66 mm[Hg]8462-4S
2026-10-21Heart rate84 /min8867-4S
2026-10-21Respiratory rate14 /min9279-1S
2026-10-21Body temperature36.6 Cel8310-5S
2026-10-21Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

Care-plan goals

GoalTarget dateStatusOutcome
Endoscopy and pancreas-protocol CT within one week, tissue diagnosis and biliary drainage within two weeks, and a tumor board plan within three weeks of presentation2026-05-04completedEndoscopy in two days, CT in three, EUS biopsy and stent in one week, tumor board in nine days, consultation at two weeks
Germline genetic testing with counseling and tumor molecular profiling resulted before surgery2026-06-29completedGermline panel negative; tumor KRAS G12D, microsatellite stable, no targetable alteration
Six cycles of modified FOLFIRINOX before surgery with no delay of more than one week2026-08-10completedSix cycles; one dose reduction of irinotecan after diarrhea; CT shows a partial response
Resection with clear margins if restaging shows no progression2026-10-05completedPancreaticoduodenectomy with vein resection; margins clear (R0)
Pain 3 out of 10 or less with a clear head for writing2026-06-29completedPain 1 to 2 out of 10 on oxycodone 5 mg once or twice a day
Weight kept within 5 percent of the weight at diagnosis through chemotherapy, with enzyme replacement and dietitian support2026-08-10completedWeight 54.2 kg before surgery, 2 percent below the weight at diagnosis
PHQ-9 below 10 throughout treatment, with support she chooses and palliative care alongside cancer treatment2026-10-05completedPHQ-9 between 6 and 8

Interventions

InterventionStatusGuideline
Medical oncology consultation within two weeks to review the endoscopy, CT and any biopsy with her and plan treatment if cancer is foundcompletedGL-NCCN-PANC-2026, GL-ASCO-PANC-2016
Urgent work-up of epigastric pain with weight loss, anemia and new diabetes: upper endoscopy within days, pancreas-protocol CT of the abdomen with CT of the chest, blood count, ferritin, liver tests, lipase and A1c; pantoprazole until the endoscopy; return at once for fresh black stools, fainting or yellow eyescompletedGL-NCCN-PANC-2026, GL-NOEL-2019
Intravenous iron for iron deficiency anemia from blood loss, with a blood count at each visitcompletedGL-NCCN-PANC-2026
Tissue and staging: EUS-guided biopsy with extra cores for molecular profiling, biliary drainage with a metal stent, CA 19-9 after the bilirubin is normal, and review at the pancreatic tumor boardcompletedGL-NCCN-PANC-2026, GL-ASCO-PANC-2016
Germline genetic testing with counseling for every patient with pancreatic cancer, and tumor molecular profiling (including KRAS, BRCA1, BRCA2, PALB2, mismatch repair, NTRK and NRG1); cascade testing offered to blood relatives only if a germline variant is foundcompletedGL-NCCN-PANC-2026, GL-ASCO-PANCGERM-2019, GL-ASCO-MPC-2020
Modified FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 400 mg/m2, fluorouracil 2400 mg/m2 over 46 hours) every two weeks for six cycles (three months) before surgery through a port, with pegfilgrastim, olanzapine-based antiemetic prevention that spares dexamethasone because of her diabetes, loperamide for late diarrhea, and neuropathy checks; CA 19-9 every two cycles and restaging CT after four and six cycles; hepatitis B, hepatitis C and HIV screening and a pregnancy test firstcompletedGL-NCCN-PANC-2026, GL-ASCO-PANC-2016, GL-ASCO-PANC-2019, GL-ASCO-ANTIEMETIC-2020, GL-ASCO-CIPN-2020, GL-ASCO-HBV-2020
Palliative care from the day of diagnosis, alongside cancer treatment: symptom control, a serious illness conversation, and planning that keeps her writing at the center; oxycodone 5 mg as needed with a bowel regimen, and EUS-guided celiac plexus neurolysis if pain becomes severecompletedGL-ASCO-PALL-2024, GL-NCCN-PANC-2026
Nutrition: dietitian review at each phase, pancrelipase with every meal and snack, small frequent meals, weight at every visitcompletedGL-NCCN-PANC-2026
Diabetes due to pancreatic disease: home glucose checks, A1c every three months, glucose checks before each cycle; insulin rather than oral agents if treatment is needed after surgery; dilated eye examination and urine albumin-to-creatinine ratio at diagnosiscompletedGL-ADA-2026, GL-CMID-2026
Venous thromboembolism: Khorana score recorded (3: pancreatic primary and hemoglobin below 10 g/dL); prophylactic apixaban offered once the duodenal bleeding has settled; enoxaparin for four weeks after surgerycompletedGL-ASCO-VTE-2023, GL-AVERT-2019
Fertility and contraception: oncofertility counseling before chemotherapy, a pregnancy test before treatment, and effective non-estrogen contraception if she becomes sexually active during treatmentcompletedGL-ASCO-FERT-2018
Pylorus-preserving pancreaticoduodenectomy with resection of the involved segment of the superior mesenteric vein after restaging shows no progressioncompletedGL-NCCN-PANC-2026, GL-ASCO-PANC-2016
Chemotherapy after surgery to complete about six months of treatment: six cycles of fluorouracil, leucovorin and irinotecan every two weeks, without oxaliplatin because of neuropathy; insulin glargine adjusted to home glucose readings; apixaban prophylaxis resumed during chemotherapy; surveillance afterwards with history, examination, CA 19-9 and CT every three to six months for two yearscompletedGL-NCCN-PANC-2026, GL-ASCO-PANC-2016, GL-ASCO-PANC-2019, GL-ASCO-VTE-2023
Distress and depression screening at each visit, plain explanations with written information, and support she chooses; she decides who is told and who receives each notecompletedGL-USPSTF-DEP-2023, GL-ASCO-PALL-2024

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Lorraine Hansberry Biographical Timeline (American Masters: Lorraine Hansberry: Sighted Eyes/Feeling Heart) PBS / WNET other
SRC-0002 Harris J. Hansberry, Lorraine Vivian (Scribner Encyclopedia of American Lives, Thematic Series: The 1960s) Encyclopedia.com (Charles Scribner's Sons) other
SRC-0003 Powers N. Hansberry, Lorraine (1930-1965) (Women in World History: A Biographical Encyclopedia) Encyclopedia.com (Gale) other
SRC-0004 Lorraine Hansberry Wikipedia other
SRC-0005 Lorraine Hansberry Biography.com (A&E Television Networks) other
SRC-0006 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the borderline resectable staging, the choice and dosing of modified FOLFIRINOX with a dexamethasone-sparing antiemetic plan, the reading of CA 19-9 after biliary drainage, the timing of apixaban after a bleeding duodenal tumor, insulin for diabetes after pancreaticoduodenectomy, and the chemotherapy after surgery without oxaliplatin.
provenance reviewnot_startedShe died in 1965; the recent-death rule does not apply. Claims rest on the PBS American Masters timeline, two reference encyclopedias, Biography.com and Wikipedia. The primary site of her cancer is recorded as R because the sources disagree; everything clinical is synthetic.
safe messaging reviewnot_startedNo mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail. No relative, friend or historical physician is given a role in the modern episode, and her private relationships are not used beyond the documented marriage.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.